Treating acute and chronic inflammatory diseases by blocking interleukin-1 beta (IL-12) activity is now part of clinical practice. There are 11 members of the IL-1 family and most induce inflammation. The function of one member, IL-1 family member 7 (IL-1F7), remains elusive. Since its discovery in 2000, there are only 9 papers. Of all members of the IL-1 family, IL-1F7 and IL-18 are the most closely related at the genomic level. There is one report that caspase-1 cleaves the recombinant IL-1F7 precursor and that processed IL-1F7 binds to the IL-18 receptor. However, there is no convincing data that recombinant IL-1F7 exhibits either pro- or anti- inflammatory activities. To avoid difficulties with recombinant forms, we transfected the IL-1F7 precursor into mouse and human cells and observed a profound suppression of endotoxin- and IL-12-induced pro- inflammatory cytokines. Silencing of endogenous IL-1F7 results in higher levels of pro-inflammatory cytokines. Importantly, IL-1F7 translocates to the nucleus. Thus, similar to IL-11 and IL-33, IL-1F7 appears to be a """"""""dual function"""""""" cytokine, that is, functional in the nucleus as well as binding to a cell surface receptor. One hypothesis being tested is whether IL-1F7 binds to the IL-18 receptor and whether such a complex recruits the inhibitory receptor, Single Ig IL-1 Related Receptor (SIGIRR) to suppress cytokines. Another hypothesis being tested is whether the nuclear function of IL-1F7 requires Smad3, the intracellular protein that mediates TGF2 signaling. In addition to testing these hypotheses in cell cultures, we have generated a strain of mice that express human IL-1F7. IL-1F7 transgenic mice are significantly protected against the systemic and local inflammation of endotoxin, dextran sodium sulfate colitis, acute myocardial ischemic infarction and contact antigen sensitization. IL-1F7 now emerges as a major inhibitory cytokine that limits inflammation during innate immune responses. We propose to use these mice to test each of the hypotheses by creating three new strains of mice, each expressing IL-1F7 but deficient in either the IL-18 receptor, SIGIRR or Smad3. The goal of this proposal is to reveal the molecular requirements for the anti-inflammatory activity of IL-1F7. IL-1F7 appears to fill a gap in understanding how the innate immune response is regulated.
of the project is one of human disease in which inflammation plays an important component. Much of inflammation is triggered by small protein molecules called cytokines that act to stimulate genes that cause inflammation. The project seeks to understand how inflammation caused by cytokines is controlled. This information will result in a better understanding of disease severity and possibly new anti-inflammatory therapies.
|Cavalli, Giulio; Dinarello, Charles A (2018) Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 281:179-190|
|Jeong, Mark Y; Lin, Ying H; Wennersten, Sara A et al. (2018) Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med 10:|
|Dinarello, Charles A (2018) Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. Immunol Rev 281:5-7|
|Cavalli, Giulio; Dinarello, Charles A (2018) Anakinra Therapy for Non-cancer Inflammatory Diseases. Front Pharmacol 9:1157|
|Wade, Morgan F; Collins, Morgan K; Richards, Denay et al. (2018) TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization. J Immunol 201:2232-2243|
|Marchetti, Carlo; Swartzwelter, Benjamin; Koenders, Marije I et al. (2018) NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther 20:169|
|Kuipers, Eline N; van Dam, Andrea D; Ballak, Dov B et al. (2018) IL-37 Expression Reduces Lean Body Mass in Mice by Reducing Food Intake. Int J Mol Sci 19:|
|Tengesdal, Isak W; Kitzenberg, David; Li, Suzhao et al. (2018) The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6. Eur J Immunol 48:1679-1686|
|Dinarello, Charles Anthony (2018) An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors. Cancer Res 78:5200-5202|
|Magenau, John M; Goldstein, Steven C; Peltier, Dan et al. (2018) ?1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood 131:1372-1379|
Showing the most recent 10 out of 565 publications